NCT02649101

Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer

Thalidomide Plus Chemotherapy Versus Chemotherapy Alone: A Phase II Study in Advanced Breast Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Sixty advanced breast cancer patients are planed to enrolled in this clinical trial. Forty patients are enrolled into thalidomide plus chemotherapy group. Twenty patients are enrolled into chemotherapy alone group. There is no restriction on chemotherapy regimen and lines.

Detailed description

The study compares the combination of thalidomide and chemotherapy with chemotherapy alone for the treatment of stage IV breast cancer. Efficacy and safety of the chemotherapy-thalidomide combination will be evaluated. Assessing the isolated effects of thalidomide in a setting where pre and post treatment serum specimens can be obtained will provide essential information about the mechanisms by which vascular endothelial growth factor(VEGF) inhibition affects tumor growth, and represents an ideal opportunity to evaluate the molecular effects of thalidomide on breast tumor.

Conditions

• Metastatic Breast Cancer

Interventions

Type	Name	Description
DRUG	Thalidomide	Thalidomide tablet 100mg qn po.
DRUG	Physician's choice chemotherapy	Investigators will declare no constraint of regimens.

Timeline

• Start date: 2015-10-01
• Primary completion: 2017-06-01
• Completion: 2017-10-01
• First posted: 2016-01-07
• Last updated: 2016-01-07

Locations

1 site across 1 country: China